EU decision on Novavax COVID-19 shot could come 'within weeks'
Reuters
Published Nov 17, 2021 10:11AM ET
(Reuters) - The European Union's drug regulator said on Wednesday it could decide on Novavax (NASDAQ:NVAX)'s COVID-19 vaccine approval "within weeks" if the data it has received from the drugmaker was sufficient to prove the shot's effectiveness.
The protein-based vaccine, branded Nuvaxovid, has been under a rolling review since February, the European Medicines Agency (EMA) said. Such reviews allow for a speedy approval.
If approved by the EMA, the shot would be the region's fifth coronavirus vaccine, joining those from Pfizer-BioNTech, Moderna (NASDAQ:MRNA), AstraZeneca (NASDAQ:AZN) and Johnson & Johnson (NYSE:JNJ).
The major approval could come much ahead of authorisation in the United States, where Novavax had to resolve manufacturing issues and expects to file for approval by the end of the year.
The EMA said two of its advisory panels were looking into various plans submitted by Novavax on risk management, and development and studies of the vaccine for use in children.
Novavax's shot received its first emergency use approval earlier this month in Indonesia. The company has also sought backing from the World Health Organization. The Philippines on Wednesday authorised emergency use of a version made by India's Serum Institute.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.